BACKGROUND: The surgical approach to colorectal liver metastases is becoming increasingly aggressive. The aim of this prospective study was to evaluate the impact of surgery on health-related quality of life (HRQoL) of patients with colorectal liver metastases. METHODS: HRQoL data from 97 patients with colorectal liver metastases were analysed. Sixty patients (group 1) had surgical treatment of the liver metastases. Seventeen patients (group 2) were shown to have inoperable disease at laparotomy. Twenty outpatients with inoperable disease were included as a control group (group 3). Two validated HRQoL instruments, the European Organization for Research and Treatment of Cancer Core questionnaire (QLQ C-30) and the EuroQol-5D, were applied. RESULTS: By 2 weeks after operation patients in group 1 showed a clear overall deterioration in HRQoL, but after 3 months most HRQoL scores had returned to baseline levels. At 2 weeks after surgery there was clear deterioration in almost all HRQoL domains in group 2, and several symptoms were still being reported at 3 months. Patients in group 3 showed hardly any deterioration in HRQoL over the 3 months. CONCLUSION: The fast recovery of HRQoL, generally within 3 months, justifies an aggressive surgical approach to colorectal liver metastases. However, careful preoperative evaluation is crucial to avoid needless laparotomy, considering the ongoing deteriorated HRQoL of group 2.
BACKGROUND: The surgical approach to colorectal liver metastases is becoming increasingly aggressive. The aim of this prospective study was to evaluate the impact of surgery on health-related quality of life (HRQoL) of patients with colorectal liver metastases. METHODS: HRQoL data from 97 patients with colorectal liver metastases were analysed. Sixty patients (group 1) had surgical treatment of the liver metastases. Seventeen patients (group 2) were shown to have inoperable disease at laparotomy. Twenty outpatients with inoperable disease were included as a control group (group 3). Two validated HRQoL instruments, the European Organization for Research and Treatment of Cancer Core questionnaire (QLQ C-30) and the EuroQol-5D, were applied. RESULTS: By 2 weeks after operation patients in group 1 showed a clear overall deterioration in HRQoL, but after 3 months most HRQoL scores had returned to baseline levels. At 2 weeks after surgery there was clear deterioration in almost all HRQoL domains in group 2, and several symptoms were still being reported at 3 months. Patients in group 3 showed hardly any deterioration in HRQoL over the 3 months. CONCLUSION: The fast recovery of HRQoL, generally within 3 months, justifies an aggressive surgical approach to colorectal liver metastases. However, careful preoperative evaluation is crucial to avoid needless laparotomy, considering the ongoing deteriorated HRQoL of group 2.
Authors: Stefan H E M Clermonts; Yu-Ting van Loon; Dareczka K Wasowicz; Barbara S Langenhoff; David D E Zimmerman Journal: J Gastrointest Surg Date: 2018-03-05 Impact factor: 3.452
Authors: Christoph Kuemmerli; Robert S Fichtinger; Alma Moekotte; Luca A Aldrighetti; Somaiah Aroori; Marc G H Besselink; Mathieu D'Hondt; Rafael Díaz-Nieto; Bjørn Edwin; Mikhail Efanov; Giuseppe M Ettorre; Krishna V Menon; Aali J Sheen; Zahir Soonawalla; Robert Sutcliffe; Roberto I Troisi; Steven A White; Lloyd Brandts; Gerard J P van Breukelen; Jasper Sijberden; Siân A Pugh; Zina Eminton; John N Primrose; Ronald van Dam; Mohammed Abu Hilal Journal: Trials Date: 2022-03-09 Impact factor: 2.279
Authors: Michael E Egger; Joanna M Ohlendorf; Charles R Scoggins; Kelly M McMasters; Robert C G Martin Journal: HPB (Oxford) Date: 2015-07-30 Impact factor: 3.647
Authors: Ronald M van Dam; Toine M Lodewick; Maartje A J van den Broek; Mechteld C de Jong; Jan Willem Greve; Rob L H Jansen; Marc H A Bemelmans; Ulf P Neumann; Steven W M Olde Damink; Cornelis H C Dejong Journal: HPB (Oxford) Date: 2013-11-07 Impact factor: 3.647
Authors: Ronald M van Dam; Edgar M Wong-Lun-Hing; Gerard J P van Breukelen; Jan H M B Stoot; Joost R van der Vorst; Marc H A Bemelmans; Steven W M Olde Damink; Kristoffer Lassen; Cornelis H C Dejong Journal: Trials Date: 2012-05-06 Impact factor: 2.279
Authors: A Chiappa; E Bertani; R Biffi; U Pace; G Viale; G Pruneri; G Zampino; N Fazio; F Orsi; G Bonomo; L Monfardini; P Della Vigna; B Andreoni Journal: Ecancermedicalscience Date: 2007-10-16